Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
The composition of the intestinal microbiota influences the development of inflammatory disorders. However, associating inflammatory diseases with specific microbial members of the microbiota is challenging, because clinically detectable inflammation and its treatment can alter the microbiota's composition. Immunologic checkpoint blockade with ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) signalling, is associated with new-onset, immune-mediated colitis. Here we conduct a prospective study of patients with metastatic melanoma undergoing ipilimumab treatment and correlate the pre-inflammation faecal microbiota and microbiome composition with subsequent colitis development. We demonstrate that increased representation of bacteria belonging to the Bacteroidetes phylum is correlated with resistance to the development of checkpoint-blockade-induced colitis. Furthermore, a paucity of genetic pathways involved in polyamine transport and B vitamin biosynthesis is associated with an increased risk of colitis. Identification of these biomarkers may enable interventions to reduce the risk of inflammatory complications following cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In parallel to microbial therapeutics, microbial signatures are being evaluated as a novel class of biomarkers, applied for stratification of efficacy and safety in clinical trials across multiple indications (Ananthakrishnan et al., 2017; Dubin et al., 2016).”
From Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers (2021) · cites this paper as Dubin et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The capacity of the microbiome to generate polyamines has also been associated with reduced toxicity of antibody to CTLA-4 in melanoma patients (22).”
From The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies (2018) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“differences may be related to several different factors – including differences in techniques used to analyze samples and reference databases used for analysis – which varied widely across the studies”
From The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy (2018) · cites this paper as Dubin et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CTLA-4 blockade (alone or in combination with anti-PD-1/PD-L1) produces toxicities in a dose-dependent fashion.22,23”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additionally, there is evidence that the microbiome is associated with development of immune-related adverse events (irAEs) following ICB7–9.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [8]
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Self-citationAdverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationUCHIME improves sensitivity and speed of chimera detection
Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C., & Knight, R. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr381 · Cited by 15,114
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624
Role of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
Metagenomic Analysis of the Human Distal Gut Microbiome
Gill, S. R., Pop, M., DeBoy, R. T., Eckburg, P. B., Turnbaugh, P. J., Samuel, B. S., Gordon, J. I., Relman, D. A., Fraser-Liggett, C. M., & Nelson, K. E. (2006) · Science · doi:10.1126/science.1124234 · Cited by 4,699
Cited by
Items 801–900 of 991
Monoclonal antibodies as adjuvant therapies for resected melanoma
Eljilany, I., García, J., Jamal, B., & Tarhini, A. A. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2484305 · Cited by 2
“Increasing dietary fiber intake and fecal microbiota transplantation (FMT) has been associated with enhanced ICI response, while emerging data suggest that FMT may also help mitigate refractory irAEs, offering a potential strategy for improving treatment outcomes [101–104].”
The Current and Future of Biomarkers of Immune Related Adverse Events
Bracamonte‐Baran, W., & Kim, S. T. (2025) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2025.01.010 · Cited by 2
Role of Human Microbiome in Development and Management of Head and Neck Squamous Cell Carcinoma
Palkovský, M., Modráčková, N., Bunešová, V., Liberko, M., Hlodáková, A., & Soumarová, R. (2025) · Cancers · doi:10.3390/cancers17132238 · Cited by 2
“Currently, the most attention regarding the impact of the gut microbiome on ICI treatment efficacy is paid to metastatic melanoma, especially to enhance the rate and depth of the response [162,183,186].”
Zhu, C., Zhang, D., Wang, Y., Zhang, C., Wang, S., Xue, J., Lan, Z., Xun, Z., Zhang, L., Chao, J., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.016 · Cited by 3
“At the bacterial level, there was no significant difference in alpha diversity, but beta diversity was significantly higher in the irAE-Yes than the irAE-No group, which is consistent with the results in other cancers [23,24].”
The impact of gut microbiota modulation on responses to immune checkpoint inhibitors in cancer
Ni, Z., & Ye, D. (2025) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.2025.02719 · Cited by 6
Wu, B., Zhao, A., Chen, W., Zhou, Y., Zhang, W., Zhang, Y., Hou, Q., Yao, N., Zhang, S., Duan, J., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1689735 · Cited by 5
“…may induce gut microbiota translocation, activate systemic inflammatory responses, and increase the risk of ICI-associated colitis and pneumonia (Dubin et al., 2016); Probiotics can mitigate these effects by maintaining intestinal barrier integrity, reducing endotoxin entry into the…”
Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum
Reyes, F., Buehning, F., Lerchner, T., Vogel, J. K., Mincu, R. I., Totzeck, M., Rassaf, T., & Michel, L. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70504 · Cited by 2
An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition
Naidoo, J., Dykema, A. G., & D’Alessio, F. R. (2018) · Journal of Clinical Investigation · doi:10.1172/jci125800 · Cited by 2
Nagasaka, M., Al-Share, B. A., Shao, Y. F., Sexton, R. E., Hallak, M. N. A., Azmi, A. S., & Sukari, A. W. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00047-4 · Cited by 3
Association of microbiota with cancer treatment
Yoshimura, K. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02302-4 · Cited by 2
Desîlets, A., & Elkrief, A. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000957 · Cited by 5
“When evaluating pre-inflammation microbiome composition, the incidence of immune-related colitis was negatively correlated with increased abundance of bacteria from the Bacteroidetes phylum [41].”
BackgroundAnticancer Effects of Washed-Dehydrated Solar Salt Doenjang on Colon Cancer-Induced C57BL/6 Mice
Lee, S., Hong, G.-H., Chung, J. H., & Park, K. (2023) · Journal of Medicinal Food · doi:10.1089/jmf.2023.k.0066 · Cited by 2
“Bacteroidetes are the predominant species found in inflammatory bowel disease 51 and CRC 52 patients.”
An Insight on Gut Flora, Colorectal Cancer Mechanism, and Treatment Strategies
Kumar, R., Kaur, A., & Rajput, D. (2023) · Advanced Gut & Microbiome Research · doi:10.1155/2023/7429949 · Cited by 4
Adiwinata, R., Tandarto, K., Tanadi, C., Waleleng, B. J., Haroen, H., Rotty, L. W. A., Gosal, F., Rotty, L., Hendratta, C., Lasut, P. F. C., et al. (2024) · Romanian Journal of Internal Medicine · doi:10.2478/rjim-2024-0015 · Cited by 2
Simunic, M., McGraw, K. L., Pavletic, S. Z., & Rashidi, A. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.10.006 · Cited by 4
Exploring molecular imaging to investigate immune checkpoint inhibitor-related toxicity
Peeters, E., van Genugten, E. A. J., Heskamp, S., de Vries, I. J. M., van Herpen, C., Koenen, H. J. P. M., Kneilling, M., van der Post, R. S., van Dop, W. A., Westdorp, H., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011009 · Cited by 2
Recent Abdominal Surgery as a Risk Factor for Unfavorable Immune-Mediated Colitis Outcomes
Ahuja, R., Shatila, M., Shah, J., Natha, C. M., Vemulapalli, V., Mittal, N., Haydel, J., Lee, I. J.-A., Rivera, A. C. U., Cruz, C. C., et al. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100767 · Cited by 2
Fidelle, M., Derosa, L., Routy, B., & Zitvogel, L. (2021) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2021.01.022 · Cited by 2
Onco-biome in pharmacotherapy for lung cancer: a narrative review
Tateishi, A., & Okuma, Y. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-299 · Cited by 2
“For example, Bacteroidetes has been reported to be more common in patients resistant to colitis caused by ipilimumab, and a higher abundance of these taxa within the gut is also generally associated with a lower incidence of toxicity (58).”
BackgroundDiet-dependent toxicity of ipilimumab in metastatic melanoma
Majenka, P., Hoffmann, M., Rötzer, I., Dimitrakopoulou‐Strauss, A., Koschny, R., Longerich, T., Enk, A., & Hassel, J. C. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.018 · Cited by 2
The role of the microbiome in precision medicine
Pincelli, J. V., Vittorelli, L. O., Stabellini, N., & Pinho, J. R. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819178-1.00002-2 · Cited by 3
An infectious diseases perspective on the microbiome and allogeneic stem cell transplant
Smibert, O. C., Trubiano, J. A., Slavin, M. A., & Kwong, J. C. (2020) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000683 · Cited by 2
Role of the Microbiome in Pancreatic Cancer
Kurtom, S., Sethi, V., & Dudeja, V. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_19 · Cited by 2
Microbiota and cancer (review of literature)
Vecherkovskaya, M. F., Tetz, G. V., & Tetz, V. (2021) · The Scientific Notes of the Pavlov University · doi:10.24884/1607-4181-2020-27-4-14-27 · Cited by 2
The Gut and Urinary Microbiota: A Rising Biomarker in Genitourinary Malignancies
Pederzoli, F., Murdica, V., Salonia, A., & Alfano, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80546-3_19 · Cited by 2
Zhao, W., Wang, X., Cheng, T., Shi, L., Wang, L., Wang, J., Xu, S., Zhang, X., Han, Y., & Huang, Z. (2024) · Ocean & Coastal Management · doi:10.1016/j.ocecoaman.2024.107079 · Cited by 2
Sekito, T., Bekku, K., Katayama, S., Watanabe, T., Tsuboi, I., Yoshinaga, K., Maruyama, Y., Yamanoi, T., Kawada, T., Tominaga, Y., et al. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102097 · Cited by 3
Novel Methods to Overcome Acquired Resistance to Immunotherapy
Zhao, X., Yuan, C., Rieth, J. M., Wangmo, D., & Subramanian, S. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-21477-7_4 · Cited by 2
Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma
Pavlick, A. C., & Weber, J. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_60 · Cited by 3
Multidisciplinary Approach to Immune-Mediated Diarrhea and Colitis From Immunotherapy for Cancer
Fan, C., & Naidoo, J. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00573 · Cited by 2
Hiddinga, B. I., Bolte, L. A., van der Leest, P., Hijmering-Kappelle, L. B. M., van der Wekken, A. J., Schuuring, E. M. D., Gaćeša, R., Hospers, G. A. P., Weersma, R. K., Björk, J. R., et al. (2023) · medRxiv · doi:10.1101/2023.10.30.23297712 · Cited by 4
“Microbial pathways for the synthesis of biotin, as well as other B-vitamins, have been reported to be enriched in those protected from ICI-induced colitis [33].”
BackgroundEquibiotic-GI Consumption Improves Intestinal Microbiota in Subjects with Functional Dyspepsia
Palacios‐González, B., Meraz‐Cruz, N., Valdez-Palomares, F., & Nambo‐Venegas, R. (2019) · Current Drug Therapy · doi:10.2174/1574885514666190212114412 · Cited by 2
Human Microbiome Modulation: A Potential Therapeutic Strategy for Pancreatic Cancer
Dhar, A. K. (2023) · Springer eBooks · doi:10.1007/978-981-19-7550-9_10 · Cited by 2
Anti-cancer alternative therapies: from inorganic nanoparticles to tumor-killing bacteria
Mihăescu, G., Constantin, M., Andronic, O., Bolocan, A., & Filip, R. (2022) · ROMANIAN BIOTECHNOLOGICAL LETTERS · doi:10.25083/rbl/27.2/3416.3421 · Cited by 1
Shatila, M., Cruz, C. C., Lu, L., Abdul-Baki, K., Baerman, E. A., Takigawa, K., Rivera, A. M., Lee, I. J.-A., Ngo, S., Sperling, G. L., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115405 · Cited by 1
Management of refractory checkpoint inhibitor-induced colitis
Zaher, A., Santos, M. J. M. N., Elsaygh, H., Peterson, S. J., Cruz, C. C., Thomas, A. S., & Wang, Y.-H. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2496431 · Cited by 1
“The successful findings with fecal microbiota transplantation in IMDC and r-IMDC open new perspectives for manipulation of the gut microbiota [30,34,77].”
Gut Microbiota, Postbiotics, and Personalized Medicine in CRC
Garg, A. K., & Madamsetty, V. S. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-86065-2_13 · Cited by 1
Shatila, M., Abdul-Baki, K., Rivera, A. C. U., Takigawa, K., Lee, I. J.-A., Sullivan, A., Gupta, T., Lu, L., Menon, R., Khan, A., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71123 · Cited by 1
“Conversely, some Bacteroides species may confer resistance to colitis [1, 22].”
Shao, S., Zheng, W., Li, X., Qi, A., Gu, Y., Gong, Y., Wang, Q., Jiao, L., & Xu, L. (2025) · Cancer Management and Research · doi:10.2147/cmar.s528555 · Cited by 1
Biscaglia, G., Gentile, A., Parente, P., Calvo, A., Fontana, R., Continisio, A., Brina, A. L. P. D., Ciardiello, D., McIlwain, G., Latiano, A., et al. (2025) · Nutrients · doi:10.3390/nu17233788 · Cited by 1
Digestive System Toxicities of Immune Checkpoint Inhibitors: Mechanisms and Clinical Implications
Lin, A., Huang, Q., Zhang, J., & Luo, P. (2026) · BIO Integration · doi:10.15212/bioi-2025-0169 · Cited by 1
Immune-modulating medications: the masquerading culprit of epididymo-orchitis
Buchinsky, D. S., Polenakovik, H. M., & Hakim, J. (2026) · BMJ Case Reports · doi:10.1136/bcr-2025-267699 · Cited by 1
Badero, O. J., Meribole, E. S., Omokore, O. A., Quadri, I. O., Kingdom, P. J., Ogbuiyi-Chima, I. C., Ogunnoiki, S. O., Samuel-Ogunnoiki, P. M., Adeyoola, O. O., Osibowale, B. T., et al. (2026) · Cureus · doi:10.7759/cureus.102283 · Cited by 2
“Increased abundance of Bacteroidetes has been associated with improved response to ipilimumab, a CTLA-4 inhibitor [37,38].”
Ziogas, D. C., Theocharopoulos, C., Martinos, A., Lyrarakis, G., Stefanou, D. T., Anastasopoulou, A. N., & Gogas, H. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01744-z · Cited by 2
“There is mounting evidence that gut microbiota may beneficially shape the efficacy of ICIs in melanoma [ 13 , 14 , 17, 23 , 24 , 40 – 50 ].”
Kengkla, K., Saeteaw, M., Sookprasert, A., & Subongkot, S. (2026) · JCO Global Oncology · doi:10.1200/go-25-00385 · Cited by 1
Han, X., Zang, D., Lin, M., Yin, Y., Liu, D., Sun, Q., & Chen, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1731931 · Cited by 1
Impact of cancer immunotherapies on oocyte health and ovarian function
Lewis, Y., Cao, Y., Higgins, J., Alesi, L. R., Winship, A., & Hutt, K. J. (2026) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2026.04.006 · Cited by 1
Diop, K., Benlaïfaoui, M., Hunter, S., Méndez-Salazar, E. O., Hakozaki, T., Richard, C., Prifti, D. K., Kourtian, S., Proulx-Rocray, F., Naimi, S., et al. (2026) · Microbiome · doi:10.1186/s40168-026-02419-4 · Cited by 4
“Baseline metagenomics profiling of melanoma patients revealed reduced alpha diversity in those developing irAE, along with a distinct beta diversity composition, consistent with previous observations [15, 16, 52].”
Decoding the power of the microbiome in human health
Kumar, M., Almohannadi, N., & Khodor, S. A. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1877371 · Cited by 1
“Notably, some of these microbes also mitigate therapy-induced colitis, suggesting dual immunotherapeutic and protective roles (Dubin et al., 2016).”
Wang, Y., Fan, C., Varatharajalu, K., Satila, M., Cruz, C. C., Sun, B., Lermi, N. O., Hayase, T., Thomas, A., Szymonowicz, K., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103044 · Cited by 1
Vozy, A., & Coutzac, C. (2016) · ONCOLOGIE · doi:10.1007/s10269-016-2658-9 · Cited by 2
“L’étude du microbiote intestinal vise à déterminer une composition fécale protectrice ou prédictive de survenue de colite [31,32].”
Backgroundd’Hargues, Y., Prinz, J., Gödel, P., Shimabukuro‐Vornhagen, A., Kochanek, M., & Böll, B. (2018) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-018-0521-z · Cited by 2
Molecular Events Behind Adverse Effects
Sun, S., & Wang, F. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_6 · Cited by 1
Immunotherapy-induced Pneumonitis: A Review of Diagnostic Workup and Treatment Guidelines
Gershner, K. A. (2020) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0000000000000373 · Cited by 1
Орлова, Р. В., Zhukova, N. V., Malkova, A. M., & Shoenfeld, Y. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100529 · Cited by 1
Microbiome - The Power House of Health and Disease
Basavaraju, M. M., Gunashree, B. S., & Srinath, S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106026 · Cited by 3
Krasnow, N. A., Chute, D. F., Falade, A. S., North, C. M., Reynolds, K. L., & Dougan, M. L. (2023) · Immunotherapy · doi:10.2217/imt-2022-0245 · Cited by 1
Li, C., Wang, L., Sun, D., Yao, T., Xian, X., & Cheng, Y. (2023) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_2078_22 · Cited by 1
Nebenwirkungen dermatoonkologischer Therapien
Hassel, J. C., & Zimmer, L. (2024) · Die Dermatologie · doi:10.1007/s00105-024-05354-3 · Cited by 1
Interaction of the Gut Microbiome With Cancer Treatment
Barrenechea, P. M. (2024) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2024.15.5.3 · Cited by 1
“Dubin and colleagues (2016) reported that an increased fecal abundance of species in the Bacteroidetes phylum and Bacteroidaceae, Rikenellaceae, and Barnesiel-laceae families correlated with less immune-mediated colitis in patients who received ipilimumab (Yervoy; Dubin et al., 2016).”
BackgroundAminzade, Z., Jafari, A., Shirani, A., Karimi, H., Naserpour, M., Javazm, A. R., Shirvani, P., Alijanzadeh, D., Samieefar, N., & Rezaei, N. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_472 · Cited by 1
Pan, Y., Zhang, T., Gu, Y., Wu, J., Hu, Z., & Gong, P. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106964 · Cited by 1
Gastrointestinal side effects of immune checkpoint inhibitors: new topic for gastroncologists
Paydaş, S. (2019) · Hematology & Medical Oncology · doi:10.15761/hmo.1000181 · Cited by 1
“Increase in bacterium phylum species at baseline has been found to be related with the low risk of colitis while Faecalibacterium prausnitzii and Gemmier formicilis have been found to be related with higher risk of colitis [61,62].”
BackgroundSide effects and management in immunotherapy based on immune checkpoint inhibitors
Li, W., Li, L.-C., & Huo, J.-G. (2020) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v28.i16.755 · Cited by 1
Bairi, K. E., Amrani, M., & Maleb, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-53821-7_5 · Cited by 1
Mechanisms of Immune-Related Adverse Events
Patil, P. D., & Velcheti, V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-67241-2.00017-3 · Cited by 1
Cancer Biomarkers and Targets in Digestive Organs
Yee, N. S., & Lee, N. P. Y. (2019) · MDPI eBooks · doi:10.3390/books978-3-03921-464-8 · Cited by 1
Diagnostic and Therapeutic Uses of the Microbiome in the Field of Oncology
Anipindi, M., & Bitetto, D. (2022) · Cureus · doi:10.7759/cureus.24890 · Cited by 3
“The specific gut microbiome protects from immunotherapy-induced colitis [84,85].”
BackgroundImmune checkpoint inhibitor-induced myocarditis
Kushnareva, E. A., Gavrilyuk, N. D., Shuginova, T. N., & Моисеева, О. М. (2022) · Russian Journal for Personalized Medicine · doi:10.18705/2782-3806-2022-2-4-35-43 · Cited by 2
Modulation of tumor environment in colorectal cancer – could gut microbiota be a key player?
Mendes, A. D., Vicente, R. S., Vitorino, M. M., Silva, M., & Costa, D. A. (2022) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2022.1021050 · Cited by 1
Antibiotics for lung disease and cancer
Arcadu, A., Silani, M. S., Amati, F., Gramegna, A., Blasi, F., & Aliberti, S. (2022) · European Respiratory Society eBooks · doi:10.1183/2312508x.10020821 · Cited by 1
Microbiota in Cancer Immunotherapy: The Next Milestone of Immuno-oncology?
Ting, N. L.-N., & Yu, J. (2023) · Springer eBooks · doi:10.1007/978-981-19-4492-5_17 · Cited by 1
Probiotics Role in Reducing GIT Cancer-Related Therapy Side Effects
Nori, W., Kassim, M. A. K., & Pantazi, A. C. (2023) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v5i.215 · Cited by 1
“This has prompted multiple researchers to use synthetic biology to redesign GM to evoke particular immune reactions against cancer and other diseases [3,9,10].”
BackgroundMAAWf: An Integrated and Visual Tool for Microbiome Data AnalysesPreprint
Zhu, S., Sun, T., Zhu, C., Qing, T., Jiang, Y., Ding, R., Su, H., Sun, Y., Xu, X., Xu, K., et al. (2020) · doi:10.21203/rs.2.23215/v1 · Cited by 1
Mujeres deshonradas: injuria y traición en la "Medea" de Eurípides
Cidre, E. R. (2000) · Anales de Historia Antigua Medieval y Moderna · doi:10.34096/ahamm.v33.4318 · Cited by 6
Editorial: Microbiota and metabolites in cancer immunotherapy
Roviello, G., & Catalano, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1093941 · Cited by 1
Xu, Y., & Jiang, A. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4597986 · Cited by 1
Biomarkers of immunotherapy-induced colitis
Seton-Rogers, S. E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.22
Enjeux et perspectives des immunothérapies : un dossier entièrement réalisé par de jeunes oncologues
Gervais, C. (2016) · ONCOLOGIE · doi:10.1007/s10269-016-2666-9
“De façon intéressante, un lien a été décrit récemment entre colite induite par anti-CTLA-4 et composition du microbiote [2].”
BackgroundImmunobiology of the Melanoma Microenvironment
Kawakami, Y., & Riker, A. I. (2018) · Springer eBooks · doi:10.1007/978-3-319-78310-9_8
The Microbiota and Ovarian Cancer
Tanyi, J. L., & Facciabene, A. (2019) · Current cancer research · doi:10.1007/978-3-030-04155-7_11
Mikrobiom und Immuntherapien bei Tumorerkrankungen
Holler, E., Weber, D., Heudobler, D., Wolff, D., & Herr, W. (2019) · Die Gastroenterologie · doi:10.1007/s11377-019-0344-3
Biomarker Testing for Immunotherapy
Naidoo, J. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.5021
Managing Checkpoint Inhibitor Symptoms and Toxicity
Pavlick, A. C., & Weber, J. S. (2019) · Springer eBooks · doi:10.1007/978-3-319-46029-1_60-1
The Gut Microbiome and Immune Modulation in The Treatment of Malignancy
Babu, H. S., West, N. P., Cripps, A. W., Sanmugarajah, J., & Mason, R. (2019) · Insights in Biomedicine · doi:10.36648/2572-5610.4.2.62
Microbiome and Microbiota in Rheumatic Disease
Attur, M., & Scher, J. U. (2019) · Springer eBooks · doi:10.1007/978-3-030-23311-2_2
The Oncomicrobiotics and the influence of the microbiota in the carcinogenesis
Bofill, I. P. (2019) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · Cited by 1
Mikrobiom und Immuntherapien bei Tumorerkrankungen
Holler, E., Weber, D., Heudobler, D., Wolff, D., & Herr, W. (2019) · best practice onkologie · doi:10.1007/s11654-019-00176-5
Ziad, E. A., & Verset, L. (2019) · Clinical Oncology and Research · doi:10.31487/j.cor.2019.05.04
Mikrobiom und Immuntherapien bei Tumorerkrankungen
Holler, E., Weber, D., Heudobler, D., Wolff, D., & Herr, W. (2020) · Wiener klinisches Magazin · doi:10.1007/s00740-019-00324-1
Integrating Metagenomics into Personalized Medicine in Dermatology
Huang, A. H., & Glick, S. A. (2020) · SKIN The Journal of Cutaneous Medicine · doi:10.25251/skin.4.6.25
“Bacteroides is also associated with resistance to checkpoint blockade-induced colitis in melanoma patients.(10) Other favorable bacteria included various species of Bifidobacterium(8), Coprococcus(1), Ruminococcus(1), and Akkermansia.”
BackgroundNon-Rheumatic Immune-Related Adverse Events
Balaji, A., Shankar, B., & Naidoo, J. (2021) · Springer eBooks · doi:10.1007/978-3-030-56824-5_10
Pharmacogenetics and personalized medicine
Núñez‐Torres, R., & González‐Neira, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820519-8.00010-7
Gastrointestinal Toxicities of Immunotherapy
Gandhi, S., Gupta, A., & Ernstoff, M. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-67241-2.00019-7
Reconstruction of Bacterial Strain Genomes from Shotgun Metagenomic Reads
Li, X. (2020) · Journal of International Crisis and Risk Communication Research
Schwab, C., Glade, J., Budczies, J., Kluck, K., Kloor, M., & Stenzinger, A. (2021) · Die Gastroenterologie · doi:10.1007/s11377-021-00531-5
Wu, M., Tang, M.-Y., Zheng, B.-H., & Zhou, S. (2021) · PubMed Central · doi:10.12182/20210960501
Gestion des toxicités de l’immunothérapie
Ricordel, C., Guen, Y. L., & Léna, H. (2021) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(21)00118-x · Cited by 1
Aarnoutse, R. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20211203ra
The Microbiome and Cancer: A Dangerous Liaison
Meisel, A. (2021) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2021.08.035
Metadata
- Authors
- Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., Pamer, E. G., & Wolchok, J. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- Broad Institute (US)
- Corresponding author
- Pamer, Eric G.
- Wolchok, Jedd D.
- ORCID
- Venue
- Nature Communications
- Published
- 2016-02-02
- Volume
- 7
- Issue
- 1
- Pages
- 10391-10391
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4740747
- OpenAlex
- W2275606382
- Cited by
- 987
- References
- 40
- Citations by year
- 2026: 56 · 2025: 76 · 2024: 83 · 2023: 117 · 2022: 145 · 2021: 128 · 2020: 131 · 2019: 112 · 2018: 71 · 2017: 48 · 2016: 19
- FWCI
- 43.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Bristol-Myers Squibb
- Memorial Sloan-Kettering Cancer Center (P30 CA008748)
- Tow Foundation
- National Institutes of Health
- Weill Cornell Medical College
- National Cancer Institute (P30CA008748)
- National Institute of General Medical Sciences (T32GM007739)
- National Institute of Allergy and Infectious Diseases (R01 AI42135, R01AI042135)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- ipilimumab, CTLA-4, metastatic melanoma, gut microbiota, Bacteroidetes, immune-related adverse events, cancer immunotherapy, polyamine transport, B vitamin biosynthesis, biomarkers, inflammatory bowel disease
- MeSH terms
- Gastrointestinal Microbiome, Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Bacteroidaceae, Colitis, Female, Humans, Male, Melanoma, Middle Aged, Prospective Studies, Risk Factors, RNA, Ribosomal, 16S, Skin Neoplasms, Sequence Analysis, RNA, Bacteroidetes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.